- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00794677
Effects of Ezetimibe on the Absorption of Oxidized Cholesterol
February 12, 2021 updated by: UCSF Benioff Children's Hospital Oakland
A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Plasma Appearance of 7-Ketocholesterol After an Oral Bolus in Patients With Primary Hypercholesterolemia
The purpose of this study is to test the effects of Zetia™ (ezetimibe) 10 milligrams (mg) on the absorption of oxysterol into the blood following a meal containing oxysterol.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
There are a number of cholesterol-lowering drugs available that can lower blood cholesterol to a healthier level.
Zetia™ (ezetimibe) 10 mg is available by prescription for the treatment of high cholesterol.
While Zetia has been shown to inhibit the absorption of dietary cholesterol into the bloodstream, its effects on oxysterol absorption from the diet have not been completely evaluated.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Berkeley, California, United States, 94705
- Cholesterol Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Not currently pregnant or lactating and is highly unlikely to conceive
- Body Mass Index (BMI) between 20-30 kilograms per meter squared (kg/m2) inclusive.
- Body weight, as reported by patient, stable (±2 kg) for >6 weeks
- Plasma low density lipoprotein cholesterol (LDL-C) between 130 and 180 milligrams per deciliter (mg/dL) inclusive. Note: One retest allowed.
- Triglyceride (TG) concentrations ≤150 mg/dL. Note: One retest allowed.
- Fasting blood glucose <110 mg/dL and hemoglobin A1c (HbA1C) ≤ 6 percent at Visit 1. Note: One retest allowed.
- Liver transaminases (ALT, AST) ≤1.5 x upper limit of normal (ULN) and no active liver disease. Note: One retest allowed.
- Creatine Phosphokinase (CPK) ≤2x ULN. Note: One retest allowed.
- Willingness to maintain a stable diet for the duration of the study.
- Can understand and comply with study procedures and signs a written informed consent.
- Patient is ≥80 precent compliant with dosing during Placebo Run-In Period or, in the opinion of the investigator, is able to maintain ≥80 percent therapy compliance during the active treatment period of the study.
Exclusion Criteria:
- Lipid-lowering therapy and replacement of this therapy with study medication is considered inappropriate by the investigator.
- Consumes an average of more than 2 alcoholic drinks per day.
- Smokes.
- Currently engages in a vigorous exercise regimen or intensive exercise bouts >4x per month.
- Treated with any other investigational drug within 30 days of Visit 1.
- Hypersensitivity or intolerance to ezetimibe or any component of this medication.
- Any condition or situation which poses a risk to the patient or interfere with participation in the study.
- Congestive heart failure.
- Uncontrolled cardiac arrhythmias.
- History of myocardial infarction, stroke, or any other clinical manifestation of coronary, cerebral, or peripheral vascular disease.
- Uncontrolled hypertension
- Impaired renal function, nephrotic syndrome or other clinically significant renal disease at Visit 1.
- Active or chronic hepatobiliary or hepatic disease.
- History of irritable bowel syndrome, ileal bypass, gastric bypass or any gastrointestinal disorder/condition associated with malabsorption.
- Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins.
- Type I or Type II diabetes mellitus.
- Disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
- Human Immunodeficiency Virus (HIV) positive.
- History of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).
- History of uncontrolled psychiatric illness or drug/alcohol abuse within the past 5 years. Individuals with psychiatric illness adequately controlled and stable on pharmacotherapy may be enrolled at the discretion of the investigator.
- Lipid-lowering agents taken within 6 weeks and fibrates taken within 8 weeks prior to visit 3.
- Cardiovascular medications are acceptable provided the patient has been on a stable regimen for at least 6 weeks prior to Visit 3 and indicates a willingness to continue the stable regimen for the duration of the study.
- Supplementation with antioxidants beyond a standard multivitamin for the duration of the study.
- Psyllium, other fiber-based laxatives, and/or over the counter (OTC) therapies known to affect serum lipid levels taken within 6 weeks of Visit 3.
- Female patients receiving hormone replacement therapy, any estrogen antagonist/agonist or hormonal contraceptives.
- Treatment with cyclosporine except for ophthalmic indication
- Anti-obesity medications such as orlistat or sibutramine taken within 3 months prior to Visit 1.
- Therapeutic doses of systemic corticosteroids except inhaled steroid therapy (for example, Pulmicort®) maintained on a stable dosing regimen for at least 6 weeks prior to randomization (Visit 3) and throughout the duration of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar Pill
Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period.
Single-blind ezetimibe placebo will be taken during the Run-In Period.
Patients will be issued one bottle containing either active drug or placebo for each treatment period.
|
Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising.
Single-blind ezetimibe placebo will be taken during the Run-In Period.
Patients will be issued one bottle containing either active drug or placebo for each treatment period.
Other Names:
|
Experimental: ezetimibe
10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period.
Single-blind ezetimibe placebo will be taken during the Run-In Period.
Patients will be issued one bottle containing either active drug or placebo for each treatment period.
|
Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising.
Single-blind ezetimibe placebo will be taken during the Run-In Period.
Patients will be issued one bottle containing either active drug or placebo for each treatment period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus
Time Frame: 6 weeks
|
Log of Area-under-the-plasma-concentration curve (AUC 0-8hrs) of 7-ketocholesterol after an oral bolus in patients with primary hypercholesterolemia after treatment with ezetimibe versus placebo
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Log(Maximal Plasma Concentration (Cmax) of 7-ketocholesterol) After an Oral Bolus
Time Frame: 6 weeks
|
Log Cmax of 7 ketocholesterol after an oral bolus in patients with primary hypercholesterolemia.
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Log(Fasting Plasma Levels of Diet-derived Oxysterols (7-ketocholesterol))
Time Frame: 6 weeks
|
6 weeks
|
|
Log (AUC of Plasma Total Cholesterol) After an Oral Bolus
Time Frame: 6 weeks
|
Area under the curve (AUC) calculated over 8 hours
|
6 weeks
|
Log (AUC of Plasma Triglyceride) After an Oral Bolus
Time Frame: 6 weeks
|
Area under the curve (AUC) calculated over 8 hours
|
6 weeks
|
Percent Change of Fasting Apolipoprotein B From Baseline
Time Frame: Baseline (placebo run-in) and 6 weeks
|
Change = [(Week 6 - baseline)/baseline value *100]
|
Baseline (placebo run-in) and 6 weeks
|
Percent Change of Fasting Low Density Lipoprotein Cholesterol From Baseline
Time Frame: Baseline (placebo run-in) and 6 weeks
|
Change = [(Week 6 - baseline)/baseline value *100]
|
Baseline (placebo run-in) and 6 weeks
|
Percent Change in Fasting High Density Lipoprotein Cholesterol
Time Frame: Baseline (placebo run-in) and 6 weeks
|
Change = [(Week 6 - baseline)/baseline value *100]
|
Baseline (placebo run-in) and 6 weeks
|
Percent Change of Fasting Non-high Density Lipoprotein Cholesterol From Baseline
Time Frame: Baseline (placebo run-in) and 6 weeks
|
Change = [(Week 6 - baseline)/baseline value *100]
|
Baseline (placebo run-in) and 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
September 1, 2008
Study Registration Dates
First Submitted
November 19, 2008
First Submitted That Met QC Criteria
November 19, 2008
First Posted (Estimate)
November 20, 2008
Study Record Updates
Last Update Posted (Actual)
March 9, 2021
Last Update Submitted That Met QC Criteria
February 12, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MM6997
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States